Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer: Clinical Trial

NCT02447263 is registered in ClinicalTrials.gov with Fuda Cancer Hospital, Guangzhou as lead sponsor.

NCT NCT02447263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02447263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer: Clinical Trial
Lead sponsor
Fuda Cancer Hospital, Guangzhou
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2015
Completion date
February 29, 2016
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer